Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.41 |
| ▸ | ACACB | O00763 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17640940 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MLYCDMTNR1AMTNR1BACACB | |
| SCHEMBL8365133 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MLYCDMTNR1AMTNR1BACACB | |
| SCHEMBL17057670 | 0.82 | ALDH1A1 (0.45) | ALDH1A1MTNR1AMTNR1BACACB | |
| SCHEMBL16351261 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MLYCDMEN1LMNAKMT2A | |
| SCHEMBL24600205 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MTNR1AMTNR1BACACB | |
| SCHEMBL16260515 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MTNR1AMTNR1BACACB | |
| SCHEMBL16864727 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MTNR1AMTNR1BACACB | |
| SCHEMBL6728949 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MLYCDMEN1LMNAKMT2A | |
| SCHEMBL6728943 | 0.79 | MLYCD (0.42) | ALDH1A1MLYCDMEN1LMNAKMT2A | |
| SCHEMBL11273630 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023196432-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230139321-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230139321-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11384064-B2 | Chemokine receptor modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11192879-B2 | Chemokine receptor modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| WO-2021106988-A1 | G9a INHIBITOR | 杏林製薬株式会社 | 2021-06-03 | — | — | WO | disclosed |
| US-20200339539-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. | 2020-10-29 | — | — | US | disclosed |
| US-20200325117-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. | 2020-10-15 | — | — | US | disclosed |
| EP-3606908-B1 | RESOLUTION OF RACEMIC BETA-AMINOSULFONE COMPOUNDS | QUIM SINTETICA S A (ES) | 2020-06-17 | — | — | EP | disclosed |
| US-10683280-B2 | Chemokine receptor modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190233397-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-08-01 | — | — | US | disclosed |
| WO-2019115624-A1 | CARBABORANE-MODIFIED GHRELIN RECEPTOR AGONISTS FOR BNCT | UNIVERSITÄT LEIPZIG (DE) | 2019-06-20 | — | — | WO | disclosed |
| US-20150299125-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20090131502-A1 | Biologically active compounds | QUIBELL MARTIN | 2009-05-21 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| WO-2008118849-A2 | HIV-1 PROTEASE INHIBITORS | UNIVERSITY OF MASSACHUSETTS (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-20230139321-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-10683280-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-20200325117-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-20150299125-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, IRAK1, BTK | ALDH1A1 841/4885MLYCD 3268/4885MTNR1A 2021/4885 |
| US-20200339539-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-11192879-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-11384064-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-20190233397-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-20090131502-A1 | Biologically active compounds | COLGALT1, SOST, COL1A1 | ALDH1A1 880/4885MLYCD 1675/4885MTNR1A 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.